The Medicines Company
If you purchased The Medicines Company securities and would like to join the action, please click "Join This Action" below.
MEDICINES COMPANY MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF THE MEDICINES COMPANY IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – MDCO
November 25, 2019.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of The Medicines Company (NASDAQ: MDCO) to Novartis AG for $85.00 per share is fair to Medicines Company shareholders. On behalf of Medicines Company shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
The Medicines Company merger investigation concerns whether Medicines Company and its Board of Directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Medicines Company shareholders; (2) determine whether Novartis AG is underpaying for Medicines Company; and (3) disclose all material information necessary for Medicines Company shareholders to adequately assess and value the merger consideration.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.